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74 Poster Session Iregimen related toxicities and GVHD. Patients transplanted for he-
mogloninopthies are reported here.Methods: Seven children with
sickle cell disease (SCD) and 3 with transfusion dependent thalasse-
mia underwent HSCT following conditioning with Campath-1H
(48 mg), fludarabine (150 mg/m2), and melphalan (140 mg/m2).
Transplant details are listed in Table 1. GVHD prophylaxis in-
cluded methotrexate, cyclosporine or tacrolimus, and methylpred-
nisolone. All but one SCD patient (with severe chronic pain) had
a stroke prior to HSCT in addition to other organ involvement. Pa-
tients were on chronic transfusion therapy for 1–12 years prior to
HSCT. Pre transplant hepatic iron levels ranged between 10.7 –
51 mg/gm dry liver weight; ferritin was 278–1520 ng/ml. Results:
All patients tolerated conditioning therapy. All recipients engrafted
donor cells except one that was infused a T-depleted product.
Transplant outcomes are summarized in Table 1. All patients
were free of disease symptoms and independent of transfusions after
HSCT. Toxicities are listed in Table 1 and were reversible. One
patient died of chronic GVHD. Conclusions: This multi-center
experience demonstrates that a reduced intensity preparative regi-
men is well tolerated and can support donor cell engraftment in pe-
diatric patients with hemoglobinopathies. Variables such as stem
cell source and cell dose need further investigation with this RIC
regimen and will be tested in trials of unrelated donor (URD) trans-
plants for hemoglobinopathy.199
RISK FACTOR ANALYSIS AND EBV LOAD SURVEILLANCE IN PEDIATRIC
BONE MARROW TRANSPLANT RECIPIENTS
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1Children’s Mercy Hospital, Kansas City, MO; 2Children’s Mercy Hospi-
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Background: Prospective monitoring of EBV load in transplant
patients is recommended for prediction of post-transplant lympho-
proliferative disease (PTLD). Current practice at our institution is
to monitor EBV viral load once pre-transplant and weekly post-
transplant until CD4 recovery. The current study was undertaken
to understand the dynamics of EBV viral load in a high-risk bone
marrow transplant (BMT) pediatric patient population and its util-
ity in predicting PTLD. Method: We performed a retrospective
chart review of EBV viral load testing in pediatric BMT patients
during a 30 month period from January 1, 2004 to June 1, 2006.
Clinical and laboratory data were collected. Realtime quantitative
PCR was performed on whole blood using Roche EBV ASR assay
on lightcycler. Patients with $ 3 of the following five risk factors
was classified as high risk for PTLD: radiation in the conditioning,
unrelated donor, T-cell depletion, graft versus host disease
(GVHD), and use of ATG. Result: A total of 682 specimens were
obtained from 25 BMTpatients for EBV viral load testing. Number
of viral load tests/patient ranged from 2 to 108 (median 21). Viral
load detected ranged from 1000 to 3,156,000 copies/ml. Number
of specimens at different viral load ranges were as follows: 468
(69%) were below detection limit of 1000 copies/ml, 196 (29%) be-
tween 1,000 to 10,000 copies/ml, 14 (2%) between 10,000 to
100,000 copies/ml and 4 (0.5%) at . 100,000 copies/ml. Sixteen
of 25 (64%) patients were classified as high risk for PTLD. Only
3/16 (19%) of high risk patients ever crossed an EBV threshold of
10,000 copies/ml and all had viral loads above 100,000 copies/ml.
The high viral loads in these 3 patients were noticed at 39, 68,
and 261 days post transplantation. The late viral load increase was
in a patient with chronic GVHD. None of the low risk patients
had viral copies that exceeded 100,000 copies/ml. None of our pa-
tients manifested PTLD. Conclusion: The absence of PTLD in
high risk pediatric BMT patients indicates that this disease entity
is uncommon. The majority of the EBV specimens were below de-
tection limit of the quantitative assay. The incidence of EBV viral
loads at values .10,000 copies/ml was low (2.5%). An alternative
and more cost effective strategy is to develop a multiplex qualitative
assay for the herpes virus group including CMV, HHV-6, EBV and
to follow up any EBV positive specimen with an EBV quantitative
PCR.200
OUTCOMES OF SECOND MYELOABLATIVE HEMATOPOIETIC STEM CELL
TRANSPLANTS IN PEDIATRIC PATIENTS WITH RECURRENT HEMATO-
LOGIC MALIGNANCIES
Lehmann, L.E.1,2, Buonanno, M.1,2, Duncan, C.N.1,2. 1Dana Farber
Cancer Institute, Boston, MA; 2Children’s Hospital Boston, Boston, MA.
Pediatric patients with hematologic malignancies who relapse
following hematopoietic stem cell transplant (HSCT) have a grim
prognosis. In this setting many patients and families inquire about
the role of a second transplant. Historical data reflecting heteroge-
neous diseases and patients suggest that about 20%may be cured by
this approach. From 7/02 through 8/07 we performed second
myeloablative HSCT on 15 patients (pts) with relapsed hematolog-
ical malignancies (6 AML, 7 ALL, 1 CML, 1 anaplastic lym-
phoma).14/15 had received TBI for the initial transplant. The
median time between transplants was 18 months (range 11 mos-
29 mos). 8 pts had a different donor for the 2nd HSCT: 2 changed
from an autologous to unrelated donor (UD), 1 had a different un-
related KIR mismatched donor, 1 had a different matched sibling
donor and 4 patients changed from a sibling donor to an UD(2
BM donors, 2 cord blood donors). 7 patients had the same donor
for both transplants although 3 patients(1 of 5 UD, 2 of 2 sib do-
nors) received peripheral blood stem cells vs BM as the stem cell
source for the 2nd HSCT. 11/15 (73%) are alive without relapse
2 months to 5 years (median 2 1/2 years) post-transplant. 11/11
had attained a complete remission prior to HSCT. 9 of the 11
had a different donor or stem cell source. 5/10 evaluable pts have
chronic GVHD, extensive in 1, limited in 4. The median perfor-
mance status of the survivors is 100% (range 80–100%).Of the 4 pa-
tients not currently in remission, 2 succumbed to regimen-related
toxicity within 3 months of the 2nd HSCT and 2 relapsed (1 died
of disease 4 yrs after 2nd HSCT and 1 is still alive 3 years following
2nd HSCT). 2nd HSCT can offer the chance of cure to pediatric
patients with leukemia/lymphoma, particularly if remission is
achieved prior to transplant and a different donor or stem cell
source is used. Acute mortality is low, potentially related to the rel-
atively long period between transplants. Chronic GVHDmay con-
tribute to but does not appear to be a prerequisite of cure and most
survivors have an excellent performance status.201
EXTRACORPOREAL PHOTOPHERESIS (ECP) IS AN EFFECTIVE THERAPY
FOR THE TREATMENT OF CHILDREN WITH STEROID REFRACTORY (SR)
CHRONIC GRAFT VS HOST DISEASE (cGVHD)
Thormann, K., Collins, J., Jacobsohn, D.A., Rademaker, A., Duerst, R.,
Schneiderman, J., Tse, W., Kletzel, M. Robert Lurie Cancer Center,
Northwestern University, Chicago, IL.
ECP is an immunemodulatory therapy that works by causing do-
nor lymphocyte apoptosis and tolerance. We hypothesize that ECP
is an effective therapy in treating SR cGVHD and allows for reduc-
tion in corticosteroids.We performed a retrospective study at Chil-
dren’sMemorialHospital to evaluate the effectiveness of ECP in SR
cGVHD in children.
There were thirteen patients with a median age 11.8 years (6–
26.2) with moderate (n 5 1) or severe (n 5 12) SR cGVHD. The
stem cell source was peripheral blood [n 5 11 (MUD 5 2)], bone
marrow [n 5 2 (MUD 5 1)]. Twelve patients were on corticoste-
roids at start of ECP and all had been on at least 2 additional drugs
(MMF, tacrolimus, rapamycin, pentostatin or azathioprine) prior.
See table for manifestations of cGVHD. ECP was started between
6/03 and 2/07. ECP treatments were given with a Therakos
UVAR XTS machine using Uvadex as a photosensitizer. A treat-
ment consisted of a single day, 4–6 hrs depending on weight and he-
matocrit. All but one patient started on 2/week treatments weekly
or every other week. Response was based on clinical improvement.
Response criteria: CR: Disappearance of all reversible cGVHD
manifestations; PR: Improvement in cGVHD manifestations; SD:
no change in manifestations; PD: worsening of any cGVHD man-
ifestations. Treatment schedule was modified and corticosteroids
were tapered as clinical improvement occurred.
Poster Session I 75Results: Patients have had a median of 10 to 124 ECP treat-
ments. The median number of treatments that enabled initial
ECP schedule taper was 22(10–124) and to achieve a CR was 62
treatments. Objective response was achieved 61% of patients (CR
in 2 patients at 8 and 15 months; PR in 6 patients). Fifteen percent
had stable disease and 23% progressed. At the time of this report 6
patients are still receiving ECP. Refer to table for organ-specific re-
sponse. Of note, six of 10 patients with lichenoid GVHD and 3 of 4
with sclerotic GVHD improved. Nine patients have been able to ta-
per corticosteroids$50% from starting dose. Five patients have
died (3 with progressive GVHD, 2 with infection/GVHD).
ECP is an alternative effectivemethod to treat moderate to severe
SR cGVHD in pediatric patients. ECP has allowed for significant
corticosteroid sparing. Prospective studies are necessary to deter-
mine optimal schedule and durability of response.
Response by Organ
System Manifestation N CR PR SD PDSkin Rash/Lichenoid 10 2 4 4 -
Fasciitis/Scleroderma 4 1 2 1 -Oral Symptoms/
lichenoid/erythema9 2 7 - -Ocular Symptoms/need
for treatment3 1 1 1 -Joints Arthralgias/
Contractures5 2 1 2 -GI Vomiting/Abdominal
Pain/Diarrhea3 - 1 2 -Liver Bilirubin . 2 8 1 2 3 2
Pulmonary Worsening
symptoms/PFTs
4 - 1 2 1202
PRELIMINARY RESULTS OF A PHASE I STUDY OF IMMUNO-CHEMO-
THERAPY (CTX) CONDITIONING WITH GEMTUZUMAB OZOGAMICIN
(GO), BUSULFAN (Bu) AND CYCLOPHOSPHAMIDE (Cy) FOLLOWED BY
ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PEDIATRIC
RECIPIENTS WITH HIGH RISK (HR) CD331 ACUTE MYELOGENOUS
LEUKEMIA (AML)
Waxman, I., Bhatia, M., Qualter, E., Jin, Z.Z., Kohl, V., Baldinger, L.,
Guerra, J., Garvin, J., George, D., Bradley, M.B., Satwani, P.,
Schwartz, J., Baxter-Lowe, L.A., Wolonik, K., Foley, S., Hawks, R.,
Militano, O., van de Ven, C., Mitchell, C.S. 1Columbia University,
New York, NY; 2UCSF, San Francisco, CA.
Survival following AlloSCT forHRAML ($CR3, induction fail-
ure [IF], refractory disease) is dismal (#10%). BuCy is standard
conditioning in children with good risk AML (Woods et al, Blood,
2001). CD33 is expressed in 80–90% of childhood AML (Creutzig
et al, Blood, 1997). GO, an anti-CD33 immunotoxin, induces re-
mission in 20–30% of relapsed/refractory childhood AML (Arceci
et al, Blood, 2005). We have reported the safety of GO as post-con-
solidation therapy after reduced intensity conditioning alloSCT in
good risk childhood AML (Roman et al, Clin Can Res, 2005). In
this study, we explore the feasibility and safety of combination im-
muno-CTX conditioning with GO and myeloablative (MA) BuCy
followed by alloSCT in pediatric recipients with HR CD331
AML. Nine patients, median age 8 yr (0.75–17 yr) with HR
CD331 AML (1 CR3, 5 IF, 3 refractory disease) were studied. Do-
nor sources were: 1 6/6 HLA-matched sibling peripheral blood
stem cell (PBSC), 1 10/10 matched unrelated donor (MUD), 7 um-
bilical cord blood (UCB) (2 6/6, 2 5/6 and 3 4/6). Conditioning was
GOon day -14, Bu (12.8mg/kg if age. 4 yr; 16mg/kg if age\4 yr)
day -7 to -4 and Cy (120 mg/kg) day -3 to -2. Unrelated alloSCT
recipients received rabbit antithymocyte globulin (8 mg/kg) from
day -5 to -2. GO was given as a dose escalation; 3 patients each re-
ceived 3 mg/m2, 4.5 mg/m2 and 6 mg/m2. All patients received
enoxaparin (1 mg/kg) from day -15 to 121 as prophylaxis for sinu-
soidal obstruction syndrome (SOS). There has been no GO dose
limiting toxicity to date. Mean neutrophil and platelet engraftment
in all patients was on day 24 6 10 (n5 8) and day 546 49 (n5 7),respectively. In the UCB group, mean neutrophil and platelet en-
graftment was on day 28 6 8 (n 5 6) and day 64 6 56 (n 5 5), re-
spectively. Mean donor chimerism on days 30 and 60 was 96%65
and 96%610, respectively. One patient (GO dose 4.5 mg/m2) de-
velopedmild SOS on day 33 that resolved without therapy. One pa-
tient died of extensive chronic graft vs. host disease on day 269 and 4
of progressive disease (day. 200), while 4 are surviving recurrence-
free at a median of 52 months. Combination immuno-CTX condi-
tioning with GO andMA BuCy followed by AlloSCT has been well
tolerated to date in children with HRCD331 AML and resulted in
$95% donor chimerism. The maximal tolerated dose (MTD) of
GO as part of a preparative regimen for MA alloSCT in children
with CD331 AML has yet to be determined. We are currently ac-
cruing patients at the next dose level of GO (7.5 mg/m2).203
UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOR HE-
MOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)
Staba Kelly, S.1, Shahlaee, A.1, Szabolcs, P.2, Driscoll, T.2, Eslin, D.3,
Kurtzberg, J.2, Martin, P.L.2. 1University of Florida, Gainesville, FL;
2Duke UniversityMedical Center, Durham,NC; 3M.D. Anderson Can-
cer Center Orlando, Orlando, FL.
Familial Hemophagocytic Lymphohistiocytosis (HLH) is a rare
disorder of immunoregulation that is usually fatal if untreated.
Characterized by fever, hepatosplenomagaly, CNS disease, coagu-
lation disorders, pancytopenia and hemaophagocytosis, onset is
usually prior to age 1. Stem cell transplant (SCT) is the only curative
option, however, most children lack suitable matched related do-
nors. Umbilical cord blood (UCB) is banked and rapidly available,
and it has a lower incidence of acute and chronic GVHD and less
viral contamination when compared with adult stem cell sources.
HLH is a disease of infants, soUCB cell dose is not a limiting factor.
All of these features make UCB an attractive stem cell source for
transplantation in this patient population, however there are few re-
ports of UCBT for HLH. Here we report the results of 10 children
treated at Duke University Medical Center and the University of
Florida with HLH who underwent unrelated donor UCBT be-
tween 1994 and 2007. Seven girls and 3 boys received their
UCBT at a median of 6 months of age, with all but one having
well controlled disease prior to transplant. Treatment prior to
UCBT was with VP-16, cyclosporine, and decadron. The prepara-
tive regimen consisted of busulfan (Bu), cyclophosphamide (Cy)/
Etoposide (VP-16)/antithymocyte globulin (ATG) in the 4most re-
cent patients, and Bu/Cy/ATG in 6. All children successfully
achieved neutrophil engraftment at a median of 17 (range 13–26)
days. The median time to platelets greater than 50,000 was 53
days, and PRBC independence was 41 days. Four children experi-
enced grade I, 1 grade II, 1 grade III and 1 Grade IV acute
GVHD, while the remainder had none. All children with grade
II-IV GVHD received steroids and the child with grade IV
GVHD also received daclizumab. Other complications included
veno-occlusive disease (VOD) in 4 children, and infections. Eight
of 10 children (80%) are surviving event free for a median of 7 years
post transplant. One died at day1 30 of hepatic failure attributed to
VOD andGVHD, the other at day1 72 of pulmonary hemorrhage,
CMV and Parainfluenza pneumonia. Survival following SCT for
HLH is reported in many series at 50–60%. VOD, organ damage
andGVHD are significant contributors to morbidity and mortality.
In combination with initial HLH treatment, UCBTwith a standard
myeloablative, chemotherapy-based preparative regimen appears
promising, providing an 80% event free survival in this pilot patient
population.204
CO-INFUSION OF MATCHED SIBLING DONOR CORD BLOOD AND BONE
MARROW AS STEM CELL SOURCE FOR ALLOGENEIC STEM CELL TRANS-
PLANTATION IN PEDIATRIC NON-MALIGNANT DISORDERS
Soni, S.1, Cowan, M.J.2, Edwards, S.3, Walters, M.C.3. 1Nationwide
Children’s Hospital, Columbus, OH; 2UCSF Children’s Hospital, San
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